Original Article | Published:

Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies

Oncogene volume 36, pages 36293639 (22 June 2017) | Download Citation

Abstract

Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation. MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies. The gain of MCM8 is associated with aggressive clinical features of several human cancers. Increased expression of MCM8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells. As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.

  2. 2.

    , , , , , . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.

  3. 3.

    , , , , , et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017. Available from: .

  4. 4.

    Network TCGAR. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011–1025.

  5. 5.

    , , , , , et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113–1120.

  6. 6.

    , , , , , . Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127–1133.

  7. 7.

    , , , , , et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134–1140.

  8. 8.

    , , , , , et al. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol 2013; 183: 1960–1970.

  9. 9.

    , , , , , et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 2013; 182: 2028–2036.

  10. 10.

    , , , , , et al. Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Pathol 2012; 180: 2240–2248.

  11. 11.

    , , , , , et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790–2799.

  12. 12.

    , , , , , et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33: 25–35.

  13. 13.

    . Gene expression alterations in human prostate cancer. Drugs Today (Barc) 2002; 38: 713–719.

  14. 14.

    , , , , , et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768–775.

  15. 15.

    , , , , , et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res 2011; 21: 515–524.

  16. 16.

    , , , , , et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011; 103: 47–60.

  17. 17.

    , , , , , et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 2005; 26: 471–479.

  18. 18.

    , , , , , . MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts. J Biol Chem 2002; 277: 33049–33057.

  19. 19.

    , . Replication licensing—defining the proliferative state? Trends Cell Biol 2002; 12: 72–78.

  20. 20.

    , , . MCM2-7 proteins are essential components of prereplicative complexes that accumulate cooperatively in the nucleus during G1-phase and are required to establish, but not maintain, the S-phase checkpoint. Mol Biol Cell 2001; 12: 3658–3667.

  21. 21.

    , , . DNA replication in quiescent cell nuclei: regulation by the nuclear envelope and chromatin structure. Mol Biol Cell 1999; 10: 4091–4106.

  22. 22.

    , , , , , et al. Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 2006; 25: 4027–4032.

  23. 23.

    . Oncogenic activity of MCM7 transforming cluster. World J Clin Oncol 2011; 2: 120–124.

  24. 24.

    , , , , , . EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595–602.

  25. 25.

    , , , , , et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090–1098.

  26. 26.

    , , , , , et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002; 62: 1123–1128.

  27. 27.

    , , , , . DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 2004; 57: 1057–1062.

  28. 28.

    , , , , , . Minichromosome maintenance protein 7: a reliable tool for glioblastoma proliferation index. Anticancer Res 2006; 26: 1071–1075.

  29. 29.

    , , , , . Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 2008; 28: 3763–3769.

  30. 30.

    , , , , , et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999; 5: 2121–2132.

  31. 31.

    , , , , , et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006; 132: 473–481.

  32. 32.

    , , , , , et al. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet 2009; 189: 37–42.

  33. 33.

    , , , , , et al. Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol 2008; 33: 245–251.

  34. 34.

    , , , , , et al. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer (Amsterdam, Netherlands) 2009; 65: 223–229.

  35. 35.

    , , , , , et al. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol 2011; 24: 277–287.

  36. 36.

    , , , , , et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 2013; 182: 339–349.

  37. 37.

    , , , , , et al. MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma. Liver Int 2012; 32: 1505–1509.

  38. 38.

    , , , , , . MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. Oncol Rep 31: 2071–2078.

  39. 39.

    , , , , , et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992; 71: 323–334.

  40. 40.

    , , , , . Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331–342.

  41. 41.

    , , , . MCM8 is an MCM2-7-related protein that functions as a DNA helicase during replication elongation and not initiation. Cell 2005; 120: 315–328.

  42. 42.

    , . Involvement of human MCM8 in prereplication complex assembly by recruiting hcdc6 to chromatin. Mol Cell Biol 2005; 25: 1560–1568.

  43. 43.

    , , , , , et al. Identification and functional characterization of a new member of the human Mcm protein family: hMcm8. Nucleic Acids Res 2003; 31: 570–579.

  44. 44.

    , , , , , et al. MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex. Nat Commun 6: 7744.

  45. 45.

    , , , , , et al. The MCM8-MCM9 complex promotes RAD51 recruitment at DNA damage sites to facilitate homologous recombination. Mol Cell Biol 2013; 33: 1632–1644.

  46. 46.

    , , , , , et al. MCM8- and MCM9-deficient mice reveal gametogenesis defects and genome instability due to impaired homologous recombination. Mol Cell 47: 523–534.

  47. 47.

    , , , , , et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest 125: 258–262.

  48. 48.

    , , , , . Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496.

  49. 49.

    , . p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.

  50. 50.

    , , . Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572–1583.

  51. 51.

    , , , , , . p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704.

  52. 52.

    , , , . Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491–1502.

  53. 53.

    , , . Physical interaction of mammalian CDC37 with CDK4. J Biol Chem 1996; 271: 22030–22034.

  54. 54.

    , , . D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505–514.

  55. 55.

    , , , . Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. EMBO J 1999; 18: 926–933.

  56. 56.

    , , , . The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996; 18: 183–190.

  57. 57.

    , , , , , et al. MCM7 interacts with androgen receptor. Am J Pathol 2008; 173: 1758–1767.

  58. 58.

    , , , , , et al. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol 2013; 230: 184–193.

  59. 59.

    , , , , , et al. p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3. J Biol Chem 2012; 287: 16890–16902.

  60. 60.

    , , , , , et al. Interaction of integrin-linked kinase and miniature chromosome maintenance 7-mediating integrin {alpha}7 induced cell growth suppression. Cancer Res 2010; 70: 4375–4384.

  61. 61.

    , , , , , et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 2007; 99: 868–880.

  62. 62.

    , , , , , et al. Expression of myopodin induces suppression of tumor growth and metastasis. Am J Pathol 2004; 164: 1799–1806.

  63. 63.

    , , . Inactivation of myopodin expression associated with prostate cancer relapse. Urology 2006; 68: 578–582.

  64. 64.

    , . Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res 2006; 66: 7414–7419.

Download references

Acknowledgements

This work was supported by grants from National Cancer Institute (RO1 CA098249) to JHL and a grant from University of Pittsburgh Cancer Institute.

Author information

Affiliations

  1. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    • D-M He
    • , B-G Ren
    • , L-Z Tan
    • , K Cieply
    • , Y P Yu
    •  & J-H Luo
  2. Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    • S Liu
    •  & G Tseng

Authors

  1. Search for D-M He in:

  2. Search for B-G Ren in:

  3. Search for S Liu in:

  4. Search for L-Z Tan in:

  5. Search for K Cieply in:

  6. Search for G Tseng in:

  7. Search for Y P Yu in:

  8. Search for J-H Luo in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to J-H Luo.

Supplementary information

Word documents

  1. 1.

    Supplementary Table 1

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2017.123

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)

Further reading